Literature DB >> 19490483

Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.

C Paillard1, A Salmon, C Curtillet, A David, P Halle, F Cachin, P Bordigoni, G Michel, R Rousseau, E Dore, F Isfan, E Merlin, E Rochette, F Demeocq, J Kanold.   

Abstract

We report results of RIC AHSCT in four adolescents with aggressive refractory HL. They all received three or four lines of therapy prior to RIC-AHSCT including autografts. At the time of RIC, they were in partial response except for one patient who had progressive chemoresistant disease. The conditioning regimen consisted of fludarabin, busulfan and ATG. They all had a matched related donor. The median follow-up was 12-16-month post-allograft. All patient transplants engrafted rapidly. The median time of hospitalization was 35 days. The median time to neutrophil recovery (>or=500/muL) was 19 days. All the patients were in complete donor chimerism at day 60. Four patients developed skin (grade <or= II) acute GvHD. All responded and all are alive. Two patients are in CR, one in PR and one relapsed six months after grafting after a PR. Each of the patients in PR received two DLI. These observations, together with the responses after DLI, suggest the presence of a graft vs. lymphoma effect in patients with advanced active HL. Prospective studies are needed to identify the patients likely to benefit most from this treatment approach. (c) 2009 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19490483     DOI: 10.1111/j.1399-3046.2009.01140.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  1 in total

1.  Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation.

Authors:  Utako Oba; Yuhki Koga; Aiko Suminoe; Toshiro Hara
Journal:  Int J Hematol       Date:  2014-08-06       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.